This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Metabolic Effects of Betaine Supplementation

This study is ongoing, but not recruiting participants.
American Diabetes Association
Information provided by (Responsible Party):
Joslin Diabetes Center Identifier:
First received: September 16, 2013
Last updated: January 5, 2017
Last verified: January 2017
Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine levels to diabetes and cardiovascular disease. Small human studies suggest benefit for non-alcoholic liver disease. In this study we will determine if administration of betaine improves metabolic measures, liver fat and/or endothelial function in humans with glucose intolerance who are overweight.

Condition Intervention Phase
Obesity Dysglycemia Drug: Betaine Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Bedside to Bench and Back: Cardiometabolic Effects of Betaine Supplementation

Resource links provided by NLM:

Further study details as provided by Joslin Diabetes Center:

Primary Outcome Measures:
  • Glucose tolerance [ Time Frame: 3 months ]
    Glucose tolerance test

  • Hepatic fat [ Time Frame: 3 months ]
    Magnetic resonance imaging

  • Endothelial Function [ Time Frame: 3 months ]
    Brachial artery reactivity

  • Insulin sensitivity [ Time Frame: 3 months ]
    Euglycemic hyperinsulinemic clamp

Estimated Enrollment: 30
Study Start Date: January 2014
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Betaine Drug: Betaine
Betaine or placebo administered orally in divided doses over 3 months.
Other Name: trimethyl glycine
Placebo Comparator: Placebo Drug: Placebo
Placebo administered orally in divided doses over 3 months

Detailed Description:
This study is a single site, prospective, randomized (1:1), double masked, placebo controlled trial to assess metabolic effects of betaine compared to placebo on glycemia and insulin sensitivity, liver fat and endothelial function.

Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1) Men and women aged 21-65 years old;
  • 2) Dysglycemia/prediabetes is defined as impaired fasting glucose (≥100 mg/dl), impaired glucose tolerance (2 hour post 75 g oral glucose load 140-200 mg/dl) or HbA1c 5.7-6.5%);
  • 3) Grade 1 obesity (BMI 27 to 36 kg/m2).

Exclusion Criteria:

  • 1) cystathionine beta-synthase (CBS deficiency);
  • 2) Presence of liver disease other than NAFLD;
  • 3) Use of medications causing steatosis;
  • 4) Known alcohol consumption ≥ 2 drink per day;
  • 5) Use of medications known to cause insulin resistance;
  • 6) Use of weight loss drugs (or program) within 3 months of screening;
  • 7) Treatment with any experimental drug within the past 6 months;
  • 8) Subjects must be willing to abstain from use of phosphodiesterase type 5 (PDE-5) inhibitors;
  • 9) Pregnancy or lactation, and women of child bearing potential must use adequate contraception;
  • 10) Surgery within 30 days of screening;
  • 11) Heart disease defined as New York Heart Association Class III or IV cardiac status or hospitalization for congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack or any revascularization within 6 months;
  • 12) Uncontrolled hypertension;
  • 13) eGFR <60; 14) History of acquired immune deficiency syndrome;
  • 15) History of malignancy within 5 years;
  • 16) Hemoglobin <12 g/dL (males), <10 g/dL (females);
  • 17) Triglycerides (TG) >500 mg/dL;
  • 18) Poor mental function or any other reason to expect patient difficulty in complying with study requirements;
  • 19) Metal clips or implants that preclude magnetic resonance imaging.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01950039

United States, Massachusetts
Joslin Diabetes Center and Brigham and Womens Hospital
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Joslin Diabetes Center
American Diabetes Association
  More Information

Responsible Party: Joslin Diabetes Center Identifier: NCT01950039     History of Changes
Other Study ID Numbers: 2013P001265
7-13-CE-17 ( Other Grant/Funding Number: American Diabetes Association 7-13-CE-17 )
Study First Received: September 16, 2013
Last Updated: January 5, 2017

Keywords provided by Joslin Diabetes Center:
Glucose Intolerance

Additional relevant MeSH terms:
Gastrointestinal Agents
Lipotropic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on September 21, 2017